In preclinical models, OPCML can potentiate the responses to anti-EGFR/anti-HER2 therapy in HER2-positive ovarian and breast cancer and, together with the phosphatase PTPRG (protein tyrosine phosphatase receptor type G), helps inactivate AXL-dependent signaling—findings that speak to both biology and translational relevance (10, 11). The gene discussed is ERBB2; the disease is breast carcinoma.